Why is Canon stock sliding today?

Canon shares fell 5.4% to ¥4,638 after it cut full-year targets, despite Q3 operating profit rising 10.3% year on year and net sales increasing 4.9%. Medical-unit supply disruptions have pushed production normalization from September 2026 into 2027 and doubled the estimated revenue impact to approximately ¥90 billion; Canon also cited tighter PCB and electronic-component supplies amid surging AI-industry demand. The stock fell while the Nikkei 225 rose sharply.

Analysis

The key risk is not simply deferred medical-equipment sales: a longer production-normalization delay makes the ¥90 billion impact more exposed to further slippage and raises the chance that delayed deliveries become lost revenue if customers switch suppliers. AI-driven competition for PCBs and electronic components may also constrain Canon’s ability to ramp even after other disruptions ease. That is a potential cross-business execution risk, but there is not enough evidence to conclude that every Canon division faces the same shortage.

Near term, the guidance reset is likely to dominate the otherwise positive quarterly operating trend; the stock’s divergence from a strong market makes relative underperformance a useful signal to monitor. Over the next 1–3 months, watch for further changes to medical production timing, the revenue-impact estimate, and evidence of customer or order loss. Over 6–18 months, successful normalization could restore deferred sales, but the recovery case weakens if component scarcity persists or competitors capture demand. Yen strength is a separate downside sensitivity to the overseas-revenue tailwind.

Contrarian view: the market may be treating a division-specific disruption as a broader earnings impairment. If the impact remains contained and normalization milestones stabilize, the selloff could prove excessive. Conversely, a schedule slip beyond 2027 would challenge the recovery thesis. No valuation or consensus data are supplied, so the current decline alone does not establish mispricing.

Key Decisions for Investors

• Consider a staged short in Canon, or a relative short against a broad Japanese-equity exposure, only if subsequent company updates extend the medical normalization timeline or raise the impact estimate. Keep risk defined: a confirmed, stable ramp schedule and evidence of retained customer demand would falsify the thesis.
• Avoid treating the headline quarterly growth as a clean earnings inflection until the guidance reduction is reconciled with medical-unit delivery timing. Track realized medical sales, order cancellations or competitor substitution, and component availability at the next update.
• Set an alert on yen appreciation: it could erode the reported overseas-revenue benefit even if medical production stabilizes. Reassess any short if the supply schedule holds and the earnings outlook improves without further guidance cuts.